External Validation, Reproducibility, and Interoperability in Digitized Traditional Diagnostic Research: A...

Traditional diagnostic research increasingly uses digital imaging, physiological signals, omics, and machine learning. Technical performance alone, however, does not establish that a method is independently validated, reproducible, or ready for clinical data integration. This study quantified the translational safeguards reported in published human studies of digitized traditional diagnostic phenotypes and signals.

We conducted a secondary cross-sectional content analysis of a predefined literature library assembled through a documented PubMed and Lens/Scopus search and screening process for a separate scoping-review project and indexed from 2000 through July 4, 2026. This was not a de novo systematic review. From the broader 195-record library, 100 formed the complete source-verifiable analysis frame because all prespecified validation, reproducibility, and interoperability outcomes could be determined from accessible source material at the audit cutoff. Records were not selected according to whether any safeguard was present or absent. Two reviewers evaluated eligibility and prespecified safeguards; 12 content exclusions left 88 eligible studies. We calculated proportions with Wilson 95% confidence intervals (CI) and an explicitly nested clinical-translation cascade.

Internal validation was reported in 51 of 88 studies (58.0%; 95% CI 47.5%-67.7%), whereas eight used an independent external cohort (9.1%; 95% CI 4.7%-16.9%). Prospective clinical evaluation was reported in 10 studies (11.4%), longitudinal outcome validation in two (2.3%), calibration in eight (9.1%), and clinical utility assessment in two (2.3%). Public datasets, analytical code, and accessible trained models were available in 13 (14.8%), three (3.4%), and two (2.3%) studies, respectively. No included study explicitly reported clinical terminology or ontology mapping, electronic health record compatibility, or Fast Healthcare Interoperability Resources mapping. The cumulative cascade was 88 eligible studies, 52 with any internal or external validation, eight with independent external validation, two also prospectively or longitudinally evaluated, one also providing a reusable resource, and none reaching interoperability.

Among the 88 eligible source-verifiable studies included in this complete-case analysis, technical validation was substantially more frequently reported than independent external validation, longitudinal clinical evaluation, reusable code or models, or documented interoperability. These findings characterize the analyzed source-verifiable literature and should not be interpreted as prevalence estimates for the broader 195-record parent library or the field as a whole. Future work should prioritize independent cohorts, clinically meaningful follow-up, reusable research resources, and standardized clinical data representation.